 |
|
 |
Half Year Report 2008
Revenues: €196.7 million ( 8.3%) / Operating result: -€16.5 million; net result: -€27.4 million / Outlook for 2008 / R&D: Neupro® (RLS) and Vimpat® (epilepsy) recommended for marketing approval
more
|
|
Three Months Report 2008
SCHWARZ PHARMA gets off to a good start
more
|
|
Full Year Report 2007
Integration of SCHWARZ PHARMA Business into UCB Group on Target
more
|
|
|  | | |
|
